Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Covid-19 Associated Coagulopathy Predicted by Thrombodynamic Markers (CoViTro-I)

NCT05330832 is registered in ClinicalTrials.gov with Federal Research Institute of Pediatric Hematology, Oncology and Immunology as lead sponsor.

NCT NCT05330832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05330832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Covid-19 Associated Coagulopathy Predicted by Thrombodynamic Markers (CoViTro-I)
Lead sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase
Observational
Overall status
Unknown status
Start date
April 1, 2020
Completion date
April 21, 2022
Enrollment
2,200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019